Cargando…
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
INTRODUCTION: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831592/ https://www.ncbi.nlm.nih.gov/pubmed/27110096 http://dx.doi.org/10.2147/BTT.S102954 |
_version_ | 1782427103861407744 |
---|---|
author | van der Hilst, Jeroen CH Moutschen, Michel Messiaen, Peter E Lauwerys, Bernard R Vanderschueren, Steven |
author_facet | van der Hilst, Jeroen CH Moutschen, Michel Messiaen, Peter E Lauwerys, Bernard R Vanderschueren, Steven |
author_sort | van der Hilst, Jeroen CH |
collection | PubMed |
description | INTRODUCTION: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. METHODS: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. RESULTS: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. CONCLUSION: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. |
format | Online Article Text |
id | pubmed-4831592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48315922016-04-22 Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature van der Hilst, Jeroen CH Moutschen, Michel Messiaen, Peter E Lauwerys, Bernard R Vanderschueren, Steven Biologics Original Research INTRODUCTION: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. METHODS: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. RESULTS: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. CONCLUSION: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. Dove Medical Press 2016-04-04 /pmc/articles/PMC4831592/ /pubmed/27110096 http://dx.doi.org/10.2147/BTT.S102954 Text en © 2016 van der Hilst et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research van der Hilst, Jeroen CH Moutschen, Michel Messiaen, Peter E Lauwerys, Bernard R Vanderschueren, Steven Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature |
title | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature |
title_full | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature |
title_fullStr | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature |
title_full_unstemmed | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature |
title_short | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature |
title_sort | efficacy of anti-il-1 treatment in familial mediterranean fever: a systematic review of the literature |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831592/ https://www.ncbi.nlm.nih.gov/pubmed/27110096 http://dx.doi.org/10.2147/BTT.S102954 |
work_keys_str_mv | AT vanderhilstjeroench efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT moutschenmichel efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT messiaenpetere efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT lauwerysbernardr efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature AT vanderschuerensteven efficacyofantiil1treatmentinfamilialmediterraneanfeverasystematicreviewoftheliterature |